文献速递前列腺癌

ARNEO:地加瑞克联合或不联合阿帕他胺新辅助治疗高危前列腺癌根治性前列腺切除术前随机II期试验

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
PubMed 文献 · Eur Urol · 2022-09-24

ARNEO为随机、安慰剂对照II期新辅助试验,2019年3月至2021年4月纳入高危前列腺癌拟行根治性前列腺切除术患者,按1:1随机接受地加瑞克+阿帕他胺(n=45)或地加瑞克+匹配安慰剂(n=44)治疗12周后手术。主要终点为微小残留病灶(MRD)比例差异,联合组显著高于对照组(38% vs 9.1%;相对风险[95%CI]=4.2[1.5-11],p=0.002)。

要点

  • 地加瑞克+阿帕他胺组MRD率显著高于地加瑞克+安慰剂组(38% vs 9.1%,p=0.002)。
  • 基线活检PTEN缺失患者MRD率显著更低(11% vs 43%,p=0.002),最终病理RCB更高(1.6 vs 0.40 cm3,p<0.0001)。
  • 新辅助治疗后PSMA PET估计肿瘤体积和SUVmax在MRD患者中更低,且与最终病理RCB显著相关(均p<0.001)。

核心结论

  • 在高危前列腺癌患者中,根治性前列腺切除术前新辅助地加瑞克联合阿帕他胺相比单用地加瑞克显著改善病理缓解(MRD和RCB)。
  • 该试验结果为新辅助III期试验提供了坚实的假设生成基础,III期试验需有足够把握度检测新辅助雄激素受体信号抑制剂治疗后长期肿瘤学结局的差异。

研究设计与样本

  • ARNEO为随机、安慰剂对照、II期新辅助试验,于2019年3月至2021年4月进行。
  • 纳入高危前列腺癌且适合根治性前列腺切除术的患者,按1:1随机分配至地加瑞克(240-80-80 mg)+阿帕他胺(240 mg/d)组(n=45)或地加瑞克+匹配安慰剂组(n=44),治疗3个月后行根治性前列腺切除术。
  • 治疗前后行盆腔18F-PSMA-1007正电子发射断层扫描(PET)/磁共振成像(MRI)。

主要发现

  • 地加瑞克+阿帕他胺组MRD率显著高于地加瑞克+安慰剂组(38% vs 9.1%;相对风险[95%CI]=4.2[1.5-11],p=0.002)。
  • 基线前列腺活检PTEN缺失患者较无PTEN缺失患者MRD率显著更低(11% vs 43%,p=0.002),最终病理RCB更高(1.6 vs 0.40 cm3,p<0.0001)。
  • 新辅助内分泌治疗后,MRD患者较无MRD患者PSMA PET估计肿瘤体积更低(1.2 vs 2.5 ml,p=0.01),最大标准化摄取值(SUVmax)更低(4.3 vs 5.7,p=0.007)。
  • 新辅助治疗后PSMA PET估计体积和PSMA PET SUVmax与最终病理RCB显著相关(均p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。
  • 患者摘要指出需要长期随访以确定改善的病理结局是否转化为更好的肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-risk prostate cancer (PCa) patients have a high risk of biochemical recurrence and metastatic progression following radical prostatectomy (RP). OBJECTIVE: To determine the efficacy of neoadjuvant degarelix plus apalutamide before RP compared with degarelix with a matching placebo. DESIGN, SETTING, AND PARTICIPANTS: ARNEO was a randomized, placebo-controlled, phase II neoadjuvant trial before RP performed between March 2019 and April 2021. Eligible patients had high-risk PCa and were amenable to RP. INTERVENTION: Patients were randomly assigned at a 1:1 ratio to degarelix (240-80-80 mg) + apalutamide (240 mg/d) versus degarelix + matching placebo for 3 mo followed by RP. Prior to and following neoadjuvant treatment, pelvic 18F-PSMA-1007 positron emission tomography (PET)/magnetic resonance imaging (MRI) was performed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the difference in proportions of patients with minimal residual disease (MRD; = residual cancer burden (RCB) ≤0.25 cm3 at final pathology). Secondary endpoints included differences in prostate-specific antigen responses, pathological staging, and change in TNM stage on prostate-specific membrane antigen (PSMA) PET/MRI following hormonal treatment. Biomarkers (immunohistochemical staining on prostate biopsy [PTEN, ERG, Ki67, P53, GR, and PSMA] and PSMA PET/MRI-derived characteristics) associated with pathological response (MRD and RCB) were explored. RESULTS AND LIMITATIONS: Patients were randomized to neoadjuvant degarelix + apalutamide (n = 45) or degarelix + matching placebo (n = 44) for 12 wk and underwent RP. Patients in the degarelix + apalutamide arm achieved a significantly higher rate of MRD than those in the control arm (38% vs 9.1%; relative risk [95% confidence interval] = 4.2 [1.5-11], p = 0.002). Patients with PTEN loss in baseline prostate biopsy attained significantly less MRD (11% vs 43%, p = 0.002) and had a higher RCB at final pathology (1.6 vs 0.40 cm3, p < 0.0001) than patients without PTEN loss. Following neoadjuvant hormonal therapy, PSMA PET-estimated tumor volumes (1.2 vs 2.5 ml, p = 0.01) and maximum standardized uptake value (SUVmax; 4.3 vs 5.7, p = 0.007) were lower in patients with MRD than in patients without MRD. PSMA PET-estimated volume and PSMA PET SUVmax following neoadjuvant treatment correlated significantly with RCB at final pathology (both p < 0.001). CONCLUSIONS: In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in a significantly improved pathological response (MRD and RCB) compared with degarelix alone. Our trial results provide a solid hypothesis-generating basis for neoadjuvant phase 3 trials, which are powered to detect differences in long-term oncological outcome following neoadjuvant androgen receptor signaling inhibitor therapy. PATIENT SUMMARY: In this study, we looked at the difference in pathological responses in high-risk prostate cancer patients treated with degarelix plus apalutamide or degarelix plus matching placebo prior to radical prostatectomy. We demonstrated that patients treated with degarelix plus apalutamide achieved a significantly better tumor response than patients treated with degarelix plus matching placebo. Long-term follow-up is required to determine whether improved pathological outcome translates into better oncological outcomes.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Devos G, Tosco L, Baldewijns M, et al. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol. 2022. PMID: 36167599. doi:10.1016/j.eururo.2022.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。